IL6 and COVID-19: Evenmore, a multicenter, randomized controlled trial of tocilizumab (IL‐6 receptor blockade, licensed for cytokine release syndrome), has been approved in patients with COVID‐19 and elevated IL‐6 in China (ChiCTR2000029765).33